Introduction
with current HPV DNA testing. Consequently, potentially high rates of overtreatment and its associated economic costs may burden healthcare systems in low-resource settings. For countries with sufficient resources to implement a sequence of tests, the WHO recommends that women with positive HPV test results may receive a triage test such as visual inspection with acetic acid (VIA) (17), with treatment provided only to women who also test positive on the triage test. Women who are HPV-positive but VIAnegative are recommended for re-screening in one year. Although there are few studies that have evaluated the diagnostic accuracy or health outcomes associated with HPV testing followed by VIA triage, countries in the early stages of implementing HPV-based screening are employing this strategy (19) .
As cervical cancer screening programs are implemented and scaled in low-resource settings, decision-makers need information on the long-term health and economic consequences of screening algorithms to develop evidence-based guidelines. Our objective was to determine the cost-effectiveness of VIA triage for HPV-positive women in resource-limited settings with different epidemiologic profiles.
Materials and Methods

Analytic overview
We used an existing individual-based Monte Carlo simulation model of the natural history of HPV and cervical cancer to estimate the lifetime health and economic outcomes associated with screening with either careHPV testing alone or careHPV testing followed by VIA triage of HPV-positive women. The model was calibrated to epidemiologic data from India, Nicaragua, and Uganda (20) . 1 Test performance for careHPV and cost data were drawn from the START-UP multi-site demonstration project conducted in India (Hyderabad), Nicaragua (Masaya Province), and Uganda (Kampala); a fourth site in India was not included in this evaluation (7, 21) . Model-projected outcomes included health 6 benefits-in terms of reductions in lifetime risk of cervical cancer incidence and gains in life expectancy-and lifetime costs (in 2011 international dollars [I$]). Cost-effectiveness ratios were expressed using incremental cost-effectiveness ratios (ICERs), defined as the additional cost of a particular strategy divided by its additional health benefit, compared with the next most costly strategy.
Dominated strategies (defined as more costly and less effective, or having higher ICERs than more effective options) were eliminated. While there is no universal criterion that defines a threshold costeffectiveness ratio, we considered per capita gross domestic product (GDP) as a benchmark; an intervention with an ICER less than the country's per capita GDP would be "very cost-effective" and less than three times per capita GDP would be "cost-effective" (22). Consistent with guidelines for costeffectiveness analysis (23) (24) (25) , we adopted a societal perspective, including costs irrespective of the payer, and discounted future costs and life-years at a rate of 3% per year to account for time preferences.
Mathematical simulation model
The natural history model of cervical carcinogenesis comprises mutually exclusive health states, including type-specific HPV infection status, grade of precancer (i.e., CIN grade 2 [CIN2] or CIN3), and stage of invasive cancer (20, 26) . Individual girls enter the model at age 9 years with a healthy cervix and transition between health states on a monthly basis until death. Transition probabilities may vary by age, HPV type, duration of infection or precancerous lesion status, and prior HPV infection. Cancer detection can occur through symptoms or via screening. Death from all-cause mortality can occur from any health state, and excess stage-dependent mortality can occur from cervical cancer after its onset.
The model tracks disease progression and regression, clinical events, and economic outcomes over the lifetime for each individual woman, which are then aggregated for analysis.
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The model parameterization process, including calibration and model fit to epidemiologic data, has been previously described (20, (26) (27) (28) . Briefly, we established baseline parameter values for the natural history component of the model using longitudinal data from a variety of settings, including ageand type-specific HPV incidence data and time-dependent rates of HPV clearance and progression by genotype (18, (29) (30) (31) (32) . To reflect heterogeneity in age-and type-specific HPV incidence between settings, as well as natural immunity following initial infection and uncertainty in progression and regression of precancer, we set plausible ranges around these input parameter values. Repeated model simulations in the absence of any intervention selected a single random value from the plausible range for each uncertain parameter, creating a unique natural history input parameter set. We then computed a goodness-of-fit score by summing the log-likelihood of model-projected outcomes for each unique parameter set to represent the quality of fit to country-specific epidemiologic data on age-specific HPV prevalence and cancer incidence (i.e., calibration targets). For each country, we selected the top 50 input parameter sets that produced good fit to the epidemiologic data to use in analyses as a form of probabilistic sensitivity analysis (26, 28, 33) . We report results as the mean of outcomes across these top 50 parameter sets.
Strategies
We assumed screening took place once in a woman's lifetime at age 35 years or three times in a lifetime at ages 30, 35, and 40 years, with 80% coverage of the target population. We compared the following strategies, which are outlined in to as "HPV-VIA"), followed by same-day cryotherapy for eligible women who were both HPV-positive and VIA-positive (Figure 2 ). In the HPV-VIA strategy, women who were HPV-positive but VIA-negative in a given screening episode were assumed to be referred to repeat screening with careHPV in one year;
we assumed 80% of women complied with follow-up screening, with HPV-positive women sent to cryotherapy (if eligible) or to further diagnostic testing (if ineligible for immediate cryotherapy) and HPVnegative women returning to routine screening intervals. For both the HPV alone and HPV-VIA strategies, we assumed that all eligible women complied with the referral to same-day cryotherapy, and that women who were ineligible for cryotherapy were referred to colposcopy and, if necessary, further treatment for women with a histological diagnosis of CIN1+, with compliance rates of 85% for each clinical contact after screening (i.e., visits for receiving screening results, colposcopy, and treatment following colposcopy). The test performance of careHPV was based on the START-UP demonstration projects (7), but the performance of VIA in known HPV-positive women was not evaluated in START-UP.
Therefore, sensitivity and specificity of VIA as a triage test for HPV-positive women (Table 1) were informed from the published literature. To bias the analysis in favor of the strategy of interest, we optimistically assumed that VIA sensitivity to detect cervical intraepithelial neoplasia grade 2 or more severe diagnoses (CIN2+) was 0.70 in women known to be HPV-positive. Based on the available literature, we assumed that VIA specificity was 0.85. Model input parameters are summarized in Table   2 .
Cost data
Cost data have been published elsewhere (20, 21) but are summarized in Table 2 . Direct medical costs of screening, diagnosis, and treatment of precancerous lesions were drawn from the START-UP study sites, and included staff time, clinical supplies, drugs, clinical equipment, laboratory staff time, laboratory supplies, and laboratory equipment. We converted local currency units to 2011 I$, a hypothetical currency that provides a means of translating and comparing costs among countries, taking into account differences in purchasing power. We assumed the careHPV test kit was a tradable good valued at US$5 per test.
Transportation costs and the cost of women's time spent traveling to, waiting for, and receiving care were dependent upon the facility level and were derived from START-UP data and the published literature, as previously described (7, 21, 27, 34, 35) . With the HPV-VIA strategy, women who tested HPV-positive incurred the direct medical costs associated with the VIA test, but we assumed that women's time spent waiting for and receiving VIA (following receipt of HPV results) was minimal. Thus, women did not incur additional time costs associated with triage testing, but women who screened positive on VIA in the HPV-VIA strategy or positive on the HPV alone strategy did incur additional waiting and procedure time for cryotherapy. Costs associated with cancer care by stage included direct medical costs, women's time costs, and transportation costs.
Scenario analysis
To explore the impact of uncertainty in cost, test performance, and treatment parameters, we evaluated the following scenarios: 1) alternative sensitivity/specificity pairs of VIA performance in HPVpositive women; 2) a lower compliance rate per visit; 3) HPV self-collection (as opposed to providercollection) at the clinic; 4) decreased direct medical costs of cryotherapy; 6) elimination of the direct medical cost of VIA triage test in HPV-positive women; 7) elimination of repeat HPV testing in 1 year for HPV-positive VIA-negative women; 8) simultaneously decreased eligibility for same-day cryotherapy and increased direct medical and women's time costs for treatment of ineligible women (i.e., cryotherapy following histological confirmation in India; LEEP procedures in Nicaragua and Uganda) (36) . To derive alternative sensitivity/specificity pairs for VIA performance in HPV-positive women, we considered the inherent tradeoff between sensitivity and specificity by computing Youden's J index values (sensitivity + 
Results
Reduction in cancer risk
Reduction in cervical cancer risk is presented, for each country, in Table 3 . In all three countries, HPV alone reduced the lifetime risk of cervical cancer more than HPV-VIA, as more women with CIN2+ and HPV infections destined to progress to CIN2+ received treatment; this finding held true whether screening occurred once or three times in a woman's lifetime. HPV alone once in a lifetime at age 35 years reduced cancer risk by 27.0% (India), 29.8% (Nicaragua), and 30.5% (Uganda), whereas HPV-VIA at age 35 years reduced cancer risk by 24.2% (India), 27.2% (Nicaragua), and 28.5% (Uganda). Screening three times in a lifetime at ages 30, 35, and 40 years was associated with substantially greater reductions in cancer risk in each country, with HPV alone yielding reductions of 48.4% in India (compared to a 44.2% reduction with HPV-VIA), 51.3% in Nicaragua (compared to a 48.6% reduction with HPV-VIA), and 52.3% in Uganda (compared to a 50.0% reduction with HPV-VIA).
Reduction in cryotherapy procedures
In all three countries, the number of immediate cryotherapy procedures associated with HPV-VIA (relative to HPV alone), was reduced. For once in a lifetime screening with HPV-VIA, the reduction in immediate cryotherapy procedures was 50.7% in India, 38.3% in Nicaragua, and 37.7% in Uganda.
Reductions in cryotherapy procedures were very similar when screening was assumed to take place with HPV-VIA three times in a lifetime.
Cost-effectiveness analysis
Cost-effectiveness results for each country are displayed in Table 3 . In India, where the burden of HPV and cervical cancer is lower than in the other settings considered, the average lifetime cost per woman was lower with HPV-VIA than with HPV alone, whether screening once or three times in a Unlike India, where HPV-VIA was less costly than HPV alone, the HPV-VIA strategy was both more costly and less effective than (i.e., dominated by) HPV alone in Nicaragua. Because cancer incidence and the cost of cancer treatment are high in Nicaragua, HPV-VIA was associated with higher costs than HPV alone due to the cost of missing HPV infections and precancers that will eventually progress to cancer. We found that screening with HPV testing alone once in a lifetime was cost-saving, while HPV testing alone three times in a lifetime cost I$200 per YLS, well below Nicaragua's per capita GDP of I$4,690.
In Uganda, as in Nicaragua, HPV-VIA was more costly and less effective than (i. 
Scenario analysis
Cost-effectiveness results for scenario analyses in India are presented in Table 4 ; results from scenario analyses in Nicaragua and Uganda-where HPV alone consistently dominated HPV-VIA as baseline assumptions were varied-are presented in Supplementary Tables S1 and S2.
In India (Table 4) , ICERs were fairly stable as VIA test sensitivity and specificity were varied relative to baseline assumptions. When VIA specificity was reduced to 0.75 (base case: 0.85) while sensitivity was held constant, ICERs remained stable as both the lifetime costs and life expectancy associated with HPV-VIA increased slightly (due to more women receiving immediate treatment with cryotherapy). When VIA sensitivity was reduced to 0.60 (base case: 0.70) and specificity held constant, screening three times in a lifetime with HPV-VIA was no longer an efficient strategy; the ICERs associated with HPV alone declined from I$460 per YLS to I$400 per YLS for once in a lifetime screening, and from I$840 per YLS to I$780 per YLS for screening three times in a lifetime. When VIA sensitivity was further reduced to 0.50 (base case: 0.70) and specificity increased to 0.90 (base case: 0.85), the ICER associated with HPV alone once in a lifetime fell to I$340 per YLS.
HPV-VIA was not an attractive strategy when we reduced visit compliance to 60% per visit (base case: 0.85%), as fewer women received follow-up HPV results in one year.
When we assumed that HPV test sensitivity was reduced due to self-collection (base case:
provider-collection) at the clinic, HPV-VIA remained less costly and also less effective than HPV alone in India, but had a slightly higher ICER than HPV alone, and was thus not an efficient strategy. As we reduced the direct medical cost of cryotherapy by 50% in India, the ICER associated with HPV-VIA once in a lifetime and HPV alone once or three times in a lifetime remained stable, but HPV-VIA three times in a lifetime was inefficient (i.e., was less effective and had a higher ICER) relative to HPV alone three times in a lifetime ( Table 4) . When we eliminated the direct medical cost of the VIA triage test, the ICERs associated with HPV alone once or three times in a lifetime increased slightly (for screening once: from I$460 per YLS to I$520 per YLS; for screening three times: from I$840 per YLS to I$930 per YLS) as the incremental costs relative to HPV-VIA increased. However, the ICERs for all strategies considered remained well below India's per capita GDP.
When we assumed there would be no repeat HPV testing in one year, the health benefits associated with HPV-VIA in India fell dramatically as women with persistent HPV infections did not receive necessary treatment, and HPV alone was more effective and more efficient (i.e., had a lower ICER) than HPV-VIA.
When we simultaneously reduced eligibility for same-day cryotherapy and increased the cost of treatment for ineligible women by 150%, the costs increased and health benefits decreased slightly for all strategies. HPV alone once in a lifetime was no longer an efficient strategy, and the ICERs for HPV-VIA once or three times in a lifetime rose to $270 per YLS and $760 per YLS; HPV alone three times in a lifetime remained the most effective strategy and cost $1,260 per YLS.
Discussion
This study represents one of the first cost-effectiveness analyses of HPV testing followed by visual triage in low-resource settings. We found that using VIA as a triage test to determine which HPVpositive women receive immediate treatment with cryotherapy is less effective at reducing cervical cancer than sending all HPV-positive women to treatment in India, Nicaragua, and Uganda. We found that HPV with VIA triage was consistently more costly and less effective than (i.e., dominated by) HPV alone in Nicaragua and Uganda, due to the costs of repeating HPV screen-and-treat in one year and the costs of missing some precancers that are destined to progress. In India, where the burden of HPV and cervical cancer is lower and the specificity of HPV testing in the START-UP study was high, HPV-VIA was an efficient strategy under baseline assumptions. Even in India, however, screening with HPV alone was a more effective strategy, and very cost-effective with an ICER well below India's per capita GDP. In both Nicaragua and Uganda, findings from scenario analyses indicated that HPV alone robustly dominated HPV-VIA whether we assumed altered VIA test performance, reduced visit compliance, HPV selfcollection at the clinic, reduced direct medical costs of cryotherapy, elimination of the additional cost of the VIA triage test, or elimination of repeat HPV testing at one year for HPV-positive/VIA-negative women. Similar scenario analyses in India found that while both the HPV-VIA and HPV alone strategies would be very cost-effective if specificity of VIA was reduced or the direct medical cost of VIA was eliminated, HPV alone consistently remained the more effective strategy. When VIA test sensitivity was reduced or when the direct medical cost of cryotherapy was reduced by 50%, HPV-VIA three times in a lifetime was no longer an efficient strategy. Under circumstances when visit compliance was reduced, HPV specimens were self-collected, or when there was no repeat HPV testing in one year for HPVpositive/VIA-negative women, HPV-VIA was not an efficient strategy in India.
There were several limitations to this analysis. Data on the performance of VIA in HPV-positive women were limited, but indicate its high variability based on setting. As the START-UP demonstration projects did not evaluate VIA as a triage test for HPV-positive women, we based VIA performance characteristics on available literature. Our review of the literature found that VIA sensitivity to detect CIN2+ in HPV-positive women was as low as 25% in Cameroon (38, 39) . The highest VIA sensitivity in HPV-positive women was 82% in a study from India (40), but this was considerably higher than the next highest sensitivity rate of 67% in Madagascar (37) . We set VIA sensitivity in HPV-positive women at 70% in order to observe outcomes under a scenario of high performance. Even under these optimal 
conditions, HPV with VIA triage was less effective than HPV testing alone in all three countries, and was only a potentially efficient strategy in India.
While the START-UP demonstration projects did not evaluate VIA as a triage strategy, we analyzed the site-specific data to determine the proportion of careHPV-positive women with CIN2+ that were also positive on VIA (i.e., the proportion that might theoretically be referred to cryotherapy with VIA triage of HPV-positive women). We found that, at the START-UP sites, 56% (57%), 63% (64%), and 71% (76%) of women with CIN2+ who were HPV-positive with provider(self)-collection in Hyderabad, Nicaragua, and Uganda, respectively, also screened positive on VIA. These data support our assertion that VIA sensitivity to detect CIN2+ in HPV-positive women is indeed optimistic at 70%.
We did not consider the quality of life implications of rare adverse events associated with treatment, and we assumed only a small proportion of women (who were ineligible for cryotherapy and had histologically confirmed CIN2+ in Nicaragua; 20% of confirmed CIN2+ in Uganda) received LEEP.
While cryotherapy is generally a safe procedure, LEEP may be accompanied by such complications as infection, bleeding, cervical stenosis, and risk of infertility or preterm birth (41, 42) ; the risk of these outcomes may be higher in low-resource settings, where LEEP is performed infrequently. Where the burden of HPV is high, even a slight risk of serious adverse events among the relatively small proportion of women referred to LEEP for CIN2+ may lead to a substantial number of cases at the population level, particularly if eligibility for cryotherapy is low. In our scenario analysis of reduced eligibility for same-day cryotherapy and increased costs of either LEEP (in Nicaragua and Uganda) or cryotherapy following histologic confirmation (in India, where LEEP was assumed to be unavailable), HPV alone three times in a lifetime remained the most effective strategy with an ICER below per capita GDP in all settings.
However, we note that further data on the frequency, safety, and quality of life implications of LEEP are needed to determine whether the benefits outweigh the risks of potential over-treatment in lowresource settings. Our costing estimates were drawn from the START-UP demonstration projects, and thus represent real-world data, albeit in a study setting. We did not include programmatic costs, but note that to achieve high test performance standards as a triage test, VIA will require substantial quality assurance and control measures that will be costly (in terms of human resources) to implement on a large scale. Due to limited data, we also did not account for changes in costs based on volume at the clinic that would accompany changes in the number of women referred to treatment.
As screening programs are implemented and scaled in low-resource settings, countries will need to design screening algorithms based on many factors in addition to the cost-effectiveness profile of a screening strategy, including acceptability, feasibility, existing infrastructure, anticipated gains relative to competing healthcare priorities, and affordability. The chronic shortage of healthcare workers in lowresource settings is a potential barrier to scale-up of HPV-based screening programs that recommend treatment for all HPV-positive women. Furthermore, gas-based cryotherapy relies on consistent resupply of gas, which is expensive to transport and not always available. We found that HPV followed by VIA triage may reduce the number of cryotherapy procedures by approximately 38% to 50%, but due to the low sensitivity of VIA and imperfect follow-up of HPV-positive/VIA-negative women, there is a corresponding decline in health benefits as fewer women with persistent HPV infection and precancer receive treatment. In Nicaragua and Uganda, the cost savings associated with fewer cryotherapy procedures were outweighed by increased costs of cancer treatment. Our findings in all three countries also indicate that, when HPV-positive/VIA-negative women did not attend recommended follow-up at one year, the health benefits associated with screening were markedly reduced. In low-resource settings where clinic visits may require substantial time and travel over long distances, compliance with followup screening in one year's time may be low, but the consequences of not receiving recommended follow-up may be serious for these women at high risk of precancer. Of note, both HPV alone and HPV- VIA may have less than the reported impact on cancer risk if cryotherapy is considerably less effective than we assume here.
While HPV testing alone may be a more effective and efficient strategy in many settings, the costs and feasibility of facilitating widespread access to cryotherapy in primary health centers may reduce the real-world effectiveness of this strategy. New treatment technologies may lessen the burden of treating all HPV-positive women, if feasibility and cost-effectiveness can be demonstrated. New ablative technologies currently undergoing testing are smaller, portable, and do not require gas.
Thermal-coagulation has been used as part of a "screen-and-treat" program in Malawi (43), and for treatment of HIV-infected women in India (44), with interim cure rates comparable to cryotherapy (41) .
The World Health Organization recommends HPV testing for countries with sufficient resources (17). HPV testing with VIA triage has received consideration as a screening algorithm in order to reduce the costs and logistical demands of cryotherapy in low-resource settings. We found that HPV testing followed by VIA triage is not necessarily less costly than HPV testing alone in settings with a high burden of HPV and cervical cancer, despite reductions in the number of immediate cryotherapy procedures. Additionally, HPV testing followed by VIA triage is less effective than HPV testing alone, as fewer women with precancer or HPV infections that would progress to precancer receive treatment, even with an optimistically sensitive VIA triage test. This analysis highlights the need for more accessible treatment options for women in low-resource settings with a high burden of HPV; only when treatment is widely available to HPV-positive women will an HPV screen-and-treat strategy be feasible. Our findings also demonstrate that, if program planners opt to use a triage strategy to reduce the number of women referred to treatment, there is a need for improved genotype restriction, biomarkers, and triage tests with better ability to predict cervical cancer risk that are also adaptable to low-resource settings. Based on current data on the performance of VIA as a triage test for HPV-positive women, this screening and triage algorithm is not likely to be cost-effective in settings with a high burden of cervical cancer. The table presents data stratified on whether the reported test performance describes the testing system (i.e., HPV testing followed by VIA) or the performance of VIA in HPV-positive women. b Study participants were HIV-infected women. c Reported test performance includes both VIA and VILI. d Data were analyzed retrospectively, so test performance is theoretical. Specificity estimates were not available. e The model inputs reflect the performance of VIA in careHPV-positive women, with HPV-positivity determined by site-specific START-UP careHPV test performance (provider-or self-collection) (see Table  2 ). Because the base case test performance parameters assumed optimistically high VIA sensitivity, we explored alternative combinations of sensitivity and specificity in scenario analyses. To reflect the inherent tradeoff between sensitivity and specificity, we assumed the study with the highest value of Youden's J index (sensitivity + specificity -1) (Catarino et al. (37) ) represented a maximum Youden's J index for VIA performance in HPV-positive women. We then explored several sensitivity and specificity pairs with Youden's J index values between the maximum index and the indices found in the remaining studies. Test performance characteristics of colposcopy in START-UP were derived from the worst diagnosis of the local pathologist relative to the worst diagnosis by a quality control pathologist (gold standard); we applied the treatment threshold of CIN1+, although this was not the treatment threshold in START-UP. To derive test performance of colposcopy, we excluded histological classifications that were inadequate or with a histological classification other than negative, CIN1, CIN2, CIN3, or cancer. Because CIN1 is not a true underlying health state in the model, performance of colposcopy in the model is based on the underlying health states of no lesion, HPV infection, CIN2, or CIN3. For a treatment threshold of CIN1, we weighted sensitivity of colposcopy for women with HPV based on the country-specific prevalence of CIN1 among women with HPV infections in the START-UP studies. e Women who screened positive but who were deemed ineligible for cryotherapy were assumed to be referred to a secondary facility for colposcopy and subsequent treatment. As described elsewhere (20) , treatment protocols were based on information from in-country clinicians familiar with standard of care and availability of and preferences for treatment options. In Hyderabad, we assumed that, upon a histologic diagnosis of CIN1, CIN2, or CIN3, women received cryotherapy at a secondary facility. In Nicaragua, we assumed that a histologic diagnosis of CIN1 was followed by cryotherapy and CIN2/3 was followed by LEEP at a secondary facility. In Uganda, we assumed that, upon a histologic diagnosis of CIN1, women received cryotherapy at a secondary facility; a histologic diagnosis of CIN2/3 was followed by cryotherapy for approximately 80% of women, and LEEP for approximately 20% of women, and treatment occurred at a secondary facility. f All costs are in 2011 international dollars (I$). In the START-UP study, procedures were performed at secondary or tertiary facilities, and costs may over-or under-estimate costs at primary health facilities due to differences in volume of procedures and overhead costs. Further details on costs are published elsewhere (20) . g This includes the cost of the careHPV test, which was assumed to be I$5. Self-collection was assumed to occur at the clinic, and the difference in costs is attributable to personnel time. h The proportion of colposcopies that were accompanied by a biopsy was drawn from START-UP data as follows: 93.1% (India); 95.6% (Uganda); and 99.5% (Nicaragua), in the absence of data from actual practice in low-resource settings. i We did not consider complication rates for cryotherapy or LEEP, as treatment complications were very rare in the START-UP demonstration projects. j Protocols for follow-up after treatment varied by country, and are published elsewhere (20) . k All cancer costs presented include the value of women's time spent pursuing care and transportation to health facilities. b Strategies are listed in order of increasing cost. c Cancer incidence reduction for each strategy reflects percentage reduction in lifetime risk of cervical cancer compared with no screening. Cancer incidence reduction, discounted lifetime cost per woman, and discounted life expectancy represent the mean across 50 input parameter sets. Dominated strategies are defined as those that are more costly and less effective or have higher ICERs than more effective options. d Base case assumptions for the parameters on which sensitivity analyses were conducted are listed in Table 1 and are as follows: HPV provider-collection (sensitivity for CIN2+/specificity: 0.89/0.95); VIA sensitivity in HPV-positive women: 0.70; VIA specificity in HPV-positive women: 0.85; Compliance rate per visit: 0.85; Direct medical cost of cryotherapy: I$38.13; Direct medical cost of VIA: I$3.55. e HPV self-collection test performance (sensitivity for CIN2+/specificity: 0.79/0.95). The direct medical cost of HPV self-collection at the clinic was slightly reduced relative to HPV provider-collection due to reduced provider time. f Eligibility for cryotherapy was reduced to 75% of women with no lesion or CIN1, 60% of women with CIN2, 49% of women with CIN3, and 15% of women with cancer (36) . The direct medical and women's procedure time cost for treatment following colposcopy and histologic confirmation were increased by 150% of the base case. We assumed that all eligible women complied with the referral to same-day cryotherapy, and that women who were ineligible for cryotherapy were referred to colposcopy and, if necessary, further treatment for women with a histological diagnosis of CIN1+. Each clinical contact for receiving results, colposcopy or treatment (for women ineligible for cryotherapy) was associated with compliance rates of 85%. 
